You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《美股業績》默沙東(MRK.US)收購Prometheus致次季轉虧 下調全年盈測
阿思達克 08-01 21:10
默沙東(MRK.US)公佈,今年第二季收入按年增長3%至150.4億美元(下同),高於市場預期的144.5億元;虧損59.8億元,每股虧損2.35元,對比去年同期爲盈利39.4億元,每股盈利1.55元。撇除收購和重組成本,公司季度每股虧損2.06元,好於市場預期的虧損2.18元。 虧損主要反映公司收購從事自身免疫性疾病治療的Prometheus相關費用102億元,即每股4.02元。默沙東稱交易已於六月中旬完成。 公司製藥業務季度收入爲134.6億元。按年增長6%,其中可用於治療多種癌症的抗體治療藥物「Keytruda」營收爲62.7億元,按年增長19%。至於新冠抗病毒藥物「molnupiravir」銷售則降83%至2.03億元。 公司將今年銷售額預測上調至586億元至596億元,略高於4月底時公佈的577億元至589億元。 而全年經調整每股盈利預期則由早前每股6.88元至7元,下調至2.95元至3.05元。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account